IL100390A - Pharmaceutical preparations that increase the bioavailability of provocol and reduce the difference in serum levels in patients - Google Patents

Pharmaceutical preparations that increase the bioavailability of provocol and reduce the difference in serum levels in patients

Info

Publication number
IL100390A
IL100390A IL10039091A IL10039091A IL100390A IL 100390 A IL100390 A IL 100390A IL 10039091 A IL10039091 A IL 10039091A IL 10039091 A IL10039091 A IL 10039091A IL 100390 A IL100390 A IL 100390A
Authority
IL
Israel
Prior art keywords
probucol
fatty acids
pharmaceutical composition
bioavailability
captex
Prior art date
Application number
IL10039091A
Other languages
English (en)
Hebrew (he)
Other versions
IL100390A0 (en
Original Assignee
Merrell Dow Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharma filed Critical Merrell Dow Pharma
Publication of IL100390A0 publication Critical patent/IL100390A0/xx
Publication of IL100390A publication Critical patent/IL100390A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL10039091A 1990-12-18 1991-12-16 Pharmaceutical preparations that increase the bioavailability of provocol and reduce the difference in serum levels in patients IL100390A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62954090A 1990-12-18 1990-12-18

Publications (2)

Publication Number Publication Date
IL100390A0 IL100390A0 (en) 1992-09-06
IL100390A true IL100390A (en) 1996-12-05

Family

ID=24523438

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10039091A IL100390A (en) 1990-12-18 1991-12-16 Pharmaceutical preparations that increase the bioavailability of provocol and reduce the difference in serum levels in patients

Country Status (17)

Country Link
EP (1) EP0563112B1 (no)
JP (1) JP3127998B2 (no)
KR (1) KR0177845B1 (no)
AT (1) ATE117200T1 (no)
AU (1) AU647563B2 (no)
CA (1) CA2097827C (no)
DE (1) DE69106892T2 (no)
DK (1) DK0563112T3 (no)
ES (1) ES2069987T3 (no)
FI (1) FI102457B1 (no)
GR (1) GR3015837T3 (no)
HU (1) HU210565B (no)
IE (1) IE65578B1 (no)
IL (1) IL100390A (no)
NO (1) NO303526B1 (no)
NZ (1) NZ240961A (no)
WO (1) WO1992010996A1 (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2517095A (en) * 1994-05-19 1995-12-18 R.P. Scherer International Corporation Solutions of aryl or heteroaryl substituted alkanoic acids in lipophilic solvents and soft gelatin capsules containing such solutions
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
US6838091B2 (en) 1998-12-18 2005-01-04 Abbott Laboratories Formulations comprising lipid-regulating agents
JP2002532539A (ja) * 1998-12-18 2002-10-02 アボット・ラボラトリーズ 脂質調節剤を含む新規な製剤
US6814977B1 (en) 1998-12-18 2004-11-09 Abbott Laboratories Formulations comprising lipid-regulating agents
US7014864B1 (en) 1998-12-18 2006-03-21 Abbott Laboratories Formulations comprising lipid-regulating agents
WO2000050029A1 (fr) * 1999-02-23 2000-08-31 Chugai Seiyaku Kabushiki Kaisha Preparations de capsules molles jonctionnees contenant des derives dihydrobenzofuranes
US6719999B2 (en) 1999-03-31 2004-04-13 Abbott Laboratories Formulations comprising lipid-regulating agents
US6372251B2 (en) 1999-06-11 2002-04-16 Abbott Laboratories Formulations comprising lipid-regulating agents
WO2005037251A1 (en) * 2003-10-17 2005-04-28 Amylin Pharmaceuticals, Inc. Self-emulsifying drug delivery systems for hydrophobic therapeutic compounds
MX2021000180A (es) 2018-06-26 2021-06-08 Ribonova Inc Métodos para tratar la disfunción mitocondrial.
US12016830B2 (en) 2022-07-01 2024-06-25 Acrotech Biopharma, LLC Pharmaceutical compositions comprising isotretinoin and processes for preparation and uses thereof
CN116617179B (zh) * 2023-05-19 2024-03-29 齐鲁制药有限公司 一种普罗布考软胶囊及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3862332A (en) * 1967-05-11 1975-01-21 Dow Chemical Co Method of lowering serum cholesterol
US4902513A (en) * 1987-07-31 1990-02-20 Jean Carvais Oral sustained release medicament

Also Published As

Publication number Publication date
ATE117200T1 (de) 1995-02-15
NO932236L (no) 1993-06-17
GR3015837T3 (en) 1995-07-31
IE914401A1 (en) 1992-07-01
WO1992010996A1 (en) 1992-07-09
FI932769A0 (fi) 1993-06-16
IE65578B1 (en) 1995-11-01
DE69106892D1 (de) 1995-03-02
FI102457B (fi) 1998-12-15
DE69106892T2 (de) 1995-05-18
ES2069987T3 (es) 1995-05-16
EP0563112A1 (en) 1993-10-06
FI102457B1 (fi) 1998-12-15
HU9301769D0 (en) 1993-09-28
KR930702965A (ko) 1993-11-29
EP0563112B1 (en) 1995-01-18
KR0177845B1 (ko) 1999-03-20
NZ240961A (en) 1994-03-25
DK0563112T3 (da) 1995-04-10
HUT64218A (en) 1993-12-28
NO303526B1 (no) 1998-07-27
FI932769A (fi) 1993-06-16
AU647563B2 (en) 1994-03-24
CA2097827C (en) 2002-07-23
HU210565B (en) 1995-05-29
JPH06503340A (ja) 1994-04-14
NO932236D0 (no) 1993-06-17
JP3127998B2 (ja) 2001-01-29
AU9067891A (en) 1992-07-22
IL100390A0 (en) 1992-09-06
CA2097827A1 (en) 1992-06-19

Similar Documents

Publication Publication Date Title
AU2002364212B2 (en) Oral capsule formulation with increased physical stability
EP2488022B1 (en) Compositions
AU647563B2 (en) Enhanced bioavailability pharmaceutical composition containing probucol
FI116714B (fi) Menetelmä valmistaa farmaseuttisia valmisteita, jotka on tarkoitettu niukkaliukoisille aktiivisille aineille
US5827536A (en) Pharmaceutical dosage formulations of fenofibrate and their applications
CA2236023C (en) Method for enhancing dissolution properties of relatively insoluble dietary supplements and product incorporating same
EP0904064B1 (en) Oral pharmaceutical compositions containing sex hormones
JP2019514852A (ja) ステロイドホルモン薬学的組成物
JP2003503440A (ja) 清澄な油を含む薬学的組成物
WO2010117873A2 (en) Progesterone solutions for increased bioavailability
JP2002537317A (ja) 疎水性治療剤の改善された送達のための組成物および方法
JP2003503440A5 (no)
AU2005271407A1 (en) Novel fenofibrate formulations and related methods of treatment
AU2011207061B2 (en) Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof
MXPA01009840A (es) Nuevas formulaciones que comprenden agentes reguladores de lipido.
AU748396B2 (en) Composition
TW202128150A (zh) ３＇—［（２ｚ）—［１—（３，４—二甲基苯基）—１，５—二氫—３—甲基—５—側氧基—４ｈ—吡唑—４—亞基］肼基］—２＇—羥基—［１，１＇—聯苯基］—３—甲酸及其鹽配製物
JP2973077B2 (ja) ビタミンｅ製剤組成物
GB2260080A (en) Gelled alginate compositions
EP2952207B1 (en) Oil based pharmaceutical compositions for oral administration
NZ708740A (en) Pharmaceutical composition
JPS6062960A (ja) ビタミンａ及びｅを含有するゼラチン軟カプセル

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired